金吾财讯 | 神威药业(02877)公告公布，截至2025年9月30日止九个月未经核数师审阅的管理账目内营业额为人民币24.15亿元，较2024年同期减少16.3%。分别是：注射液产品的营业额减少23.6%至人民币7.86亿元；软胶囊产品的营业额减少13.7%至人民币3.37亿元；颗粒剂产品的营业额减少14.5%至人民币3.91亿元；中药配方颗粒产品的营业额减少11.8%至人民币7.26亿元；及其他剂型产品的营业额减少6.1%至人民币1.75亿元。以产品剂型分析，截至2025年9月30日止九个月，注射液产品、软胶囊产品、颗粒剂产品及中药配方颗粒产品分别占集团之营业总额约32.5%、14.0%、16.2%及30.1%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.